Home | Back to newsletter main page

Case Comprehensive Cancer Center Newsletter

February 1, 2010

MESSAGE FROM THE DIRECTOR

I received a document from AACR that has been circulated to the AACR Public Affairs Legislative Committee. It relates to a new piece of legislation by Representative Capps that was introduced last year, and may have legs this year. Regardless of its passage, this legislation provides a roadmap for a public policy oriented perspective on the need for a more public screening/detection/survivorship effort by the NCI and HHS. (Click here to view document)

I have provided only a summary that I received with two caveats:

  1. The italics were added by Ron DePinho of Dana Farber, who has useful perspective on a number of issues raised.
  2. The bold text is my added emphasis on the points that I think would impact us most.

My further perspectives are as follows: In the context of maturing our approach to individualized therapeutic clinical trials, we need to consider the evolution and complexity of both early screening and risk assessment, followed by premalignant management, interventions that are risk adjusted, and also management of advanced cancers using biomarker-driven therapeutics.

Please note the emphasis in the following areas:

  • Standards and support for biospecimens to be used in research tissue handling is critical for diagnostics as well as gene discovery
  • Development of a centralized IRB with facilitated local review
  • Intervention studies into survivorship in areas of late effects, neurocognitive and family impact. But, as Ron points out, the bulk of the focus may be on biomarkers for rare and hard to treat cancers using 50% survival as an endpoint, which could skew the research effort considerably, while developing demonstration projects and centers of excellence for detection development and validation.

I wonder whether we should give consideration to the following:

  • How to promote biomarker development and validation coupled with the need to standardize biospecimen collection storage and analysis (IHC for phosphoproteins is an example of a problem)
  • Clinical interventions around biomarkers for early detection with stratified responses
  • Use of therapeutic agents for "theranostics" or therapeutic predictive markers that predict response – the individualized therapeutics model.

How might we develop a strategy for cancer center investments?

I look forward to a dialogue with individual cancer center members and program leaders on these topics.

Stanton Gerson, MD
Director, Case CCC
slg5@case.edu


KUDOS

A paper co-authored by Harihara Baskaran and biomedical engineering doctoral student Saheli Sarkar, titled Insights Into the Roles of Non-Muscle Myosin IIA in Human Keratinocyte Migration, was recognized as a 2009 Outstanding Cellular and Molecular Bioengineering Paper at the Biomedical Engineering Society's Annual Meeting.

Georgia Wiesner, MD and Timothy O'Brien, MD have been named CWRU Master Teachers for the 2009-2010 academic year. The School of Medicine initiated this program last year to recognize individuals who over a long period of time and with sustained effort have contributed to innovation and excellence in medical and/or graduate educate.


FUNDING OPPORTUNITY– Samuel Waxman Cancer Research Foundation

The Case CCC has been invited to submit ONE application for a Samuel Waxman Cancer Research Foundation Institute Without Walls grant. Investigators of the Foundation have long been interested in differentiation therapy of cancer- the notion that the cancer cell can be re-programmed to re-acquire aspects of normal cell differentiation including terminal cell division and programmed cell death. In 2010, the Foundation will offer several grants of up to $100,000 per year to fund novel research along these lines.

Applicants must be established investigators with a tenure-track or tenured appointment, holding as PI at least one grant from a major funding source, such as NIH, NSF, DOD or ACS. The applicant may hold a K08, K99/R00, or other major career transition grant, such as those from Burroughs Wellcome Foundation or HHMI. The goal of the program is to leverage existing cancer research expertise into translational and collaborative cancer research.

Please send a one-page proposal and biosketch to Bonnie West (bonnie.west@case.edu by Monday, February 15. Completed applications are due to Waxman Foundation April 1.

For more information, please click here.


MARK YOUR CALENDARS– Oncomine Workshop

Mark your calendars for an Workshop on Thursday, March 4 at 2:00 pm in WRB 1413. Come hear presenter, Oncomine's Gary Daubresse, explain how this powerful software and database can benefit your proposal writing and cancer research. Light refreshments will be served. This workshop is presented by the Case CCC/Gene Expression and Genotyping Facility (GEGF) and ONCOMINE. Contact Patrick Leahy patrick.leahy@case.edu, 368-0761 with any questions.


MARK YOUR CALENDARS– State-of-the-Science Conference on Colorectal Cancer Screening and Post-Conference Press Telebriefing

An NIH State-of-the-Science Conference on Enhancing Use and Quality of Colorectal Cancer Screening will be held February 2-4, 2010. After weighing the results of a systematic literature review, expert presentations, and audience input, an impartial, independent panel will prepare a statement of its collective assessment of the available evidence with regard to six predetermined conference questions. The panel's press telebriefing will highlight its findings and implications for the public.

For details, please click here.


FUNDING OPPORTUNITY– CanLiv's 2010 Translational Research Grants Program

CanLiv, the Hepatobiliary Cancers Foundation, is accepting applications for the 2010 Translational Research Grants Program for Cancers of the Bile Ducts and Gallbladder Young Investigators Award. This award provides funding to promising new investigators to encourage and promote translational research in cancers of the gallbladder and/or bile ducts (cholangiocarcinoma). CanLiv's definition of translational research is hypothesis-driven research that seeks to expand understanding of carcinogenic mechanisms in cancers of the liver, gallbladder and/or bile ducts and has significant likelihood to imminently lead to new therapeutic options for patients.

Applicants must hold an MD, DO, PhD or DSci degree and be in their first to third year of a full time, primary faculty appointment in a clinical, basic, or translational science department at an academic medical institution. For foreign-trained physicians or scientists, equivalency will be determined on a case by case basis. Applicants must be tenure-track scientists at the level of Assistant Professor, but cannot be tenured or under review for tenured academic positions at the time of application submission.

Deadline March 5

For details, please click here.

EVENTS

**All events are open to anyone interested in attending

February 1

Pathology Graduate Student Dissertation Defense
Debasmita Mandal
PhD Candidate, Levine Lab, Pathology
CWRU
Topic: Tuning of Interleulin 13 Signaling in Intestinal Epithelial Cells Via IL-13Ra2-Induced MAP Kinase Activation and Induction of Reactive Oxygen Species
12:00 pm WRB 1413

Structural Biology Seminar
Shachi Gosavi, PhD
Center for Theoretical Biological Physics
UC San Diego
Topic: Exploring the Energy Landscape of Protein Folding and Function with Coarse Grained Models
1:00 pm SOM E501

SDIG Meeting
John Archer, PhD, MSc
Faculty, Life Sciences
University of Manchester
Topic: Quantitative Deep Sequencing and Detecting HIV-1 Drug Resistance
2:30 pm WRB 1402

Physiology & Biophysics Seminar
Arie Horowitz, DSc
Assistant Professor, Molecular Cardiology
CWRU/ Cleveland Clinic
Topic: Molecular Mechanisms of Vessel Sprouting
4:00 pm SOM E501


February 2

Taussig Cancer Institute Core Curriculum Series
Frederic Reu, MD
Associate Staff, Hematologic Oncology & Blood Disorders
Cleveland Clinic
Topic: Multiple Myeloma
12:00 pm R3-002 Cleveland Clinic


February 3

Grand Rounds
Ted Parran, MD
Clinical Associate Professor, Medicine
CWRU/ UH
Topic: Pain Management and Addiction in Heme/Onc Clinic
8:00 am Lerner B-151


February 4

Taussig Cancer Institute Core Curriculum Series
David Peereboom, MD
Associate Professor, Hematology & Medical Oncology
CWRU/ Cleveland Clinic
Topic: Primary Brain Tumors
12:00 pm R3-002 Cleveland Clinic

Neurosciences Seminar
David Friel, PhD
Associate Professor, Neurosciences
CWRU
Topic: Two Examples of Ca2+ Signaling in Neurons and Neuronal Circuits
12:10 pm BRB105


February 5

Hem/Onc Fellows Seminar
Lisa Arfons, MD
Fellow, Div. of Hem/Onc
CWRU/ UH
Topic: Thalidomide and Refractory Gastrointestinal Bleeding
8:00 am Wearn 137

Taussig Cancer Institute Grand Rounds
Robert Amdur, MD
Professor and Residency Program Director, Radiology
University of Florida
Topic: Advances in Radiation Oncology
8:00 am R3/002-003 Cleveland Clinic

Olof Pearson Lecture
V. Craig Jordan, PhD
Scientific Director, Lombardi Comprehensive Cancer Center
Chair, Translational Cancer Research
Georgetown University
Topic: Estrogen in the Life and Death of Breast Cancer
12:00 pm WRB 1413

Cancer Center Research in Progress Seminar
Seunghwan Lim, PhD
Research Associate, Kim Lab, Pediatrics
CWRU/ UH
Topic: Type III TGF-β Receptor Links IL-1β and TGF-β Signaling Through TRAF6 Association
4:00 pm WRB 3-136

more

For a complete listing of LRI seminars click here.


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

Case CCC Scientific Retreat
July 9-10
The Lodge at Sawmill Creek Resort


ADDITIONAL UPCOMING SEMINARS & EVENTS

12th International Symposium on Anti-Angiogenic Agents: Angio 2010 Recent Advances and Future Directions in Basic and Clinical Cancer Research
February 4-6
Hyatt Regency La Jolla, San Diego, CA
Details

AACR-JCA 8th Joint Conference on Cancer Genomics, Epigenomics, and the Development of Novel Therapeutics
February 5-9
Hilton Waikoloa Village, Waikoloa, HI
Details

13th Annual Meeting of the Translational Research Cancer Centers Consortium
March 1-2
Blackwell Inn, Columbus, OH
Details

AACR 101st Annual Meeting
April 17-21
Washington, DC
Details


FUNDING OPPORTUNITY– DOD Ovarian Cancer Research Program

The DOD is accepting applications for Ovarian Cancer Research Program (OCRP) Pilot Awards. FY10 OCRP is supporting innovative ideas that will drive the field forward and reduce the burden of ovarian cancer in the future. In addition, the OCRP is promoting unique partnerships and fostering the next generation of investigators in ovarian cancer research. These awards support conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer forward. Research priorities should include a testable hypothesis based on strong scientific rationale. Successful projects should provide a catalyst to expand or modify current thinking and/or approaches in ovarian cancer research.

Pre-Application Deadline: March 11

For more information, please click here.


FUNDING OPPORTUNITY– DOD Prostate Cancer Research Program

The DOD is accepting applications for Prostate Cancer Research Program (PCRP) Idea Development and Synergistic Idea Development Awards. The goals of the FY10 program are aimed towards eliminating death and suffering from prostate cancer. All applications for these awards should address at least one of the following PCRP overarching challenges: develop effective treatments for advanced prostate cancer, and distinguish lethal from indolent disease.

Pre-Application Deadline: March 3

For more information, please click here.


MESSAGE FROM DR. ERNEST BORDEN– Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)

The CTC/CEC core has initiated several investigator-initiated pilot studies and has begun to see planning for those which will be externally funded. We continue to encourage you, however, to develop new ideas for exploring and validating this technology. In addition to quantitation of these rare circulating cells, we are also now ready to undertake isolation of macromolecules for analysis. The isolated preparations will be provided back to you for assessment of expression in your laboratory or that of a collaborator.

These proposals should involve pilot studies for which technical feasibility and preliminary data needs to be established in order to lead to external funding and would normally be for evaluation of 10-20 samples. We will require the following information (limited to 1 page) for consideration for pilot studies:

  1. PI
  2. Study Title and Objective/Rationale (Tumor, CEC or CTC, cell quantitation or RNA)
  3. Eligible patients; desired number of samples
  4. Plans for obtaining external support (NIH, pharma, foundation based) for definitive study
  5. Contact information for research RN for scheduling and consenting purposes

If you have any questions please do not hesitate to discuss with John Pellecchia or myself. Please submit your 1 page proposals to John Pellecchia at pellecj@ccf.org. Final approval to proceed with your pilot study will be granted by Dr. Derek Raghavan and myself and should normally be available within a week of submission.


NCI CANCER BULLETIN

Featured Article
St. Jude, Washington University Launch Genome Project for Childhood Cancers

Cancer Research Highlights
Adjuvant Chemotherapy May Benefit Older Patients with Colorectal Cancer

Brain Cancer, Like Other Cancers, Has Distinct Subtypes

Strategy May Enhance Umbilical Cord Blood Transplants

Acupuncture Reduces Joint Pain in Some Women with Breast Cancer

Genome Scans for Pancreatic Cancer Yield Clues to Risk

Guest Director's Update: Dr. Paulette S. Gray, Director, NCI Division of Extramural Activities
Major Grant Application Changes Now in Effect


MARK YOUR CALENDARS– NCI 3rd Annual Biospecimen Research Network Symposium

Registration is now open and abstracts are being accepted for NCI's 3rd Annual Biospecimen Research Network Symposium, Advancing Cancer Research Through Biospecimen Science, March 24-25 in Bethesda, Maryland. The symposium will address the significant impact of pre-analytical biospecimen variables on cancer research and molecular medicine. Hosted by NCI's Office of Biorepositories and Biospecimen Research, the meeting will bring together leaders in the fields of biospecimen research, genomics, proteomics, oncology, pathology, biobanking, hospital administration and pharmaceutics as well as patient advocates.

For details, please click here.


FUNDING RESOURCES- Links to Funding Resources and Updated NIH Forms Available on Case CCC Website

The Case CCC Funding Resources page has links to the following important resources:

Be sure to bookmark the links for easy future reference.


FUNDING OPPORTUNITY– ACS Cancer Research Fellowship

A Call for Applications was recently released for the ACS Cancer Research Fellowship, which is intended to strengthen the field of cancer research by attracting outstanding clinicians and scientists into careers in oncology upon completion of their specialty training and to engage them in basic or clinical academic cancer research. The fellowship is not intended for those already on a research track.

Deadline: March 3

For more information, please click here.



CALL FOR APPLICATIONS– 2010 NASA Space Radiation Summer School

Applications are now being accepted for the 2010 NASA Space Radiation Summer School. Up to 15 students will be selected for the course to be held this summer at the Brookhaven National Laboratory (BNL) in Long Island, NY from May 20 – June 11. The goal of the course is to provide scientific and practical information to students and scientists who are either new to the NASA program or to charged particle radiobiology. At the completion of the summer school, students will have received the full complement of training required to conduct their own experiments at BNL.

Both foreign nationals and US citizens may apply to the program. All selected students must satisfy BNL and Department of Energy safety and security requirements in order to be admitted. Due to the intense nature of the course, applicants must demonstrate oral and written proficiency in the English language.

Deadline: February 28

For more information, please click here.


FUNDING OPPORTUNITY— Title Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas (RC4)

NIH is accepting applications for the "Title Recovery Act Limited Competition: NIH Director's Opportunity for Research in Five Thematic Areas" (RC4) (RFA-OD-10-005).

This program will support projects that address research endeavors in specific areas that will benefit from significant three-year funds without the expectation of continued NIH funding beyond this period. The research supported by the program should have high short-term impact, and a high likelihood of enabling growth and investment in biomedical research and development, public health, and health care delivery.

This FOA solicits applications proposing to develop and implement critical research innovations in one or more of the following five thematic areas:

  1. Applying Genomics and Other High Throughput Technologies
  2. Translating Basic Science Discoveries into New and Better Treatments
  3. Using Science to Enable Health Care Reform
  4. Focusing on Global Health
  5. Reinvigorating the Biomedical Research Community

Only applications for projects that require $500,000 or more in total costs per year are expected to be considered for funding.

LOI Deadline: February 15 (requested, not required)
Proposal Deadline: March 15

For details, please click here.

Case CCC Leadership would like to review potential responses, and can assist in developing themes as responsive to the RFA.


shRNA CLONE AVAILABILITY

The Small Molecule Screening Core (SMSC) has negotiated an opportunity to order shRNA clones from Sigma (in the form of glycerol stocks) for LRI and CWRU researchers for a very low price on a per clone basis. To order, please contact Anna Kondratova (kondraa@ccf.org, 445-3503). The next order will be in March, but existing clones can be purchased at any time.

Also, the SMSC has small aliquots of secondary antibodies available for purchase; each set is conjugated with DyLight 488 and DyLight 594 fluorescent dyes (Jackson ImmunoResearch Laboratories). The antibodies work well in place of fluorescein/Alexa488 & Texas Red conjugates.

Please click here for more information.


FACULTY CANDIDATE SEARCH– Associate Director for Basic Research

The Case CCC is currently accepting applications for the position of Associate Director for Basic Research. As we continue our search, we ask that people in the Cancer Center community encourage any qualified candidate to apply for the position. If you would like to nominate someone for the position, please contact Tracy Rehl (tracy.rehl@case.edu).

Click here to view the job description.


CASE CCC ON FACEBOOK AND LINKEDIN– Join Us!

We are always trying to foster communication and collaboration across the cancer center community any way that we can. The Case CCC has set up a page on Facebook and LinkedIn, so please become a fan of us on Facebook or join our group on LinkedIn, and encourage others to do so as well. Please help us spread the word.

We encourage you to post events, relevant news articles, items of discussion, etc… Your feedback is appreciated!


CALL FOR APPLICATIONS– K12 Clinical Oncology Research Training Program

The Case CCC invites applications for its two-year NCI-funded K12 Clinical Oncology Research Training Program, led by Stanton Gerson, MD, Director, and Alvin Schmaier, MD, Co-Director.

This career development program provides interdisciplinary training in clinical and translational oncology research for clinical oncologist who are interested in pursuing academic research careers as oncology physician scientists.

Application Deadline: February 28
Start Date: July 1

For more information and application materials, please click here.


PREVIOUSLY ANNOUNCED FUNDING OPPORTUNITIES

ACS Ohio Division Joseph S. Silber Student Summer Fellowship
Deadline: February 3

Multiple Myeloma Research Foundation 2009 Seniors Award Program
Deadline: February 3

Leukemia Research Foundation Hollis Brownstein Research Grants Program
Deadline: February 15

Ohio Cancer Research Associates
Deadline: February 19

AICR Investigator Initiated Grants
Deadline: February 19

AICR Matching Grants
Deadline: February 19

AICR Postdoctoral Awards
Deadline: February 19


Hope Street Kids
Deadline: March 1

IOTF Oncology Product Research/Review Fellows
Deadline: May 30

IOTF Cancer Prevention Fellows
Deadline: September 1

AACR Scholar-in-Training Awards - Special Conferences
Deadline varies

NCI Short-Term Scientist Exchange Program
Deadline: Open

James S. McDonnell Foundation
Deadline: Open


NIH Bulletin – Notices and Funding Opportunities

UPDATE TO RFA-OD-10-001: ARRAOS Recovery Act Limited Competition: Behavioral Economics for Nudging the Implementation of Comparative Effectiveness Research: Clinical Trials (RC4) - Announcement of Additional Funds Availability and Increased Allowable Total Costs (NOT-OD-10-053)

Clarification of NOT-OD-10-034: Availability of Recovery Act Funds for Competitive Revision Applications for Small Business Innovation Research and Small Business Transfer Technology Research Grants (R43/R44 and R41/R42) through the NIH Basic Behavioral and Social Science Opportunity Network (OppNet) (NOT-OD-10-054)

Request for Information (RFI): To Solicit Input on Priorities for the NIH Basic Behavioral and Social Science Opportunity Network (OppNet)(NOT-OD-10-055)

Review Considerations for Applications and Awards under the New NIH Guidelines for Human Stem Cell Research (NOT-OD-10-056)

Notice of Correction to PA-09-186 (NOT-OD-10-057) National Institutes of Health

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.

If you have trouble viewing this page, click here to view the newsletter online on our website.